What is Synecor?
Headquartered in Menlo Park, California, and Research Triangle Park, North Carolina, Synecor operates as a dedicated incubator and accelerator for cardiovascular innovation. The company bridges the gap between early-stage research and market-ready medical technology by providing the necessary infrastructure, management expertise, and capital to nascent biomedical ventures. By focusing exclusively on the cardiovascular domain, Synecor maintains a high-authority position in the healthcare sector, effectively de-risking complex development projects for its partners and stakeholders.
The firm's business model centers on identifying high-potential cardiovascular technologies and nurturing them through the rigorous regulatory and clinical validation processes. This strategic approach ensures that only the most viable innovations reach the clinical stage, thereby maximizing the potential for long-term patient impact and commercial success.
How much funding has Synecor raised?
Synecor has raised a total of $1.5M across 1 funding round:
Angel/Seed
$1.5M
Angel/Seed (2000): $1.5M, investors not publicly disclosed
Key Investors in Synecor
Delphi Ventures
A private venture capital firm specializing in providing equity financing and strategic business expertise to early-stage biomedical and healthcare companies.
Deutsche Banc Alex. Brown
The U.S. investment banking division of Deutsche Bank, providing comprehensive financial services and capital market access to institutional clients.
DB Capital Partners
A merchant banking affiliate of Deutsche Bank AG that leverages global resources to provide strategic investment and financial support to growing enterprises.
What's next for Synecor?
Following this major enterprise-level funding, Synecor is expected to scale its internal operations and expand its portfolio of cardiovascular research initiatives. The influx of capital will likely be directed toward enhancing the firm's laboratory capabilities and strengthening its clinical trial support infrastructure. As the company moves into its next phase of growth, the focus will remain on identifying breakthrough technologies that address unmet needs in heart health. By leveraging its deep industry expertise and robust network of institutional partners, Synecor is poised to maintain its leadership in the biomedical accelerator space, driving significant value for both the healthcare ecosystem and its investors.
See full Synecor company page
